Joel brings over 35 years of clinical, academic and pharmaceutical research and medical affairs experience to his role as Chief Medical Advisor to Arrivo. Joel was a community and academic psychiatrist, consultant to public and private industry, and the Head of the Depression Clinic and Clinical Trials Specialist at the Center for Addiction and Mental Health, University of Toronto before joining Eli Lilly in 1999. During his 20 years at Eli Lilly, Joel held various global team roles in neuroscience drug development and commercialization, working in mood and anxiety disorders, schizophrenia, chronic pain, Alzheimer’s, and migraine. He also directed the Intercontinental Neuroscience Medical Organization for 4 years. Joel has engaged with governments, regulators, payers, scientific organizations, physicians, educators and advocacy groups. He has published nearly 100 articles and has presented at international conferences and academic institutions.

Most recently Joel was the CMO of MindCure, a psychedelic research company. He is on the scientific review board of the Alzheimer’s Drug Discovery Foundation, served as a scientific advisor to the Weston Family Foundation Brain Institute, and serves as an advisor to drug, device and technology development companies.